Earnings call transcript: Arjo Q1 2026 shows stable growth amid challenges

Arjo reported Q1 2026 organic growth of 3.8%, in line with guidance, but gross margin fell 110 bps to 42.6% due to U.S. tariffs and FX effects. Adjusted EBIT declined to SEK 190 million from SEK 208 million, while adjusted EBITDA was flat at 16.9% and cash conversion improved sharply to 52.7% from 41.3%. Management kept the strategic outlook constructive, targeting a clearer future strategy for approval and communication in the second half of 2026.

Analysis

The key read-through is not the quarter itself but the tension between resilient demand and a rising cost stack. If management can hold growth while tariff/FX pressure is still manageable, the next leg is likely margin recovery via pricing and mix, not volume acceleration; that matters because it suggests the market is underestimating operating leverage once the new product mix normalizes. The South Africa bed project is a useful signal: large multi-site wins are less about one-off revenue and more about proving the company can bundle product, logistics, and installation into higher-quality revenue that competitors with weaker service footprints may struggle to match.

The real risk is that the current margin drag could persist longer than investors expect if tariffs, FX, and energy costs all move in the same direction. That combination tends to hit medical equipment suppliers in a delayed way: first gross margin, then working capital as customers stretch payment on larger projects, then capital allocation if management leans harder on pricing and inventory buffers. The U.S. flu-season headwind also matters because it suppresses the most cyclical part of the mix; if flu normalizes into next winter, the company gets an automatic operating tailwind without needing to outperform on share.

Consensus likely treats this as a cleanly neutral print, but the second-order effect is that a stable quarter buys management time to reset strategy without forcing a balance-sheet defense. The strategic review into 2H26 is a potential catalyst, but only if it surfaces concrete simplification, SKU rationalization, or channel discipline; otherwise it will be discounted as corporate narrative. Near term, the most important variable is whether management can demonstrate that the gross-margin gap is mostly transitory mix/tariff noise rather than a structurally lower price realization environment.

Key Decisions for Investors

• Long SEB / Arjo only as a tactical expression if you can buy into weakness over the next 1-2 weeks; the setup is a low-volatility, cash-generative name where downside is likely capped unless guidance breaks, but upside is limited until the 2H26 strategy catalyst.
• Pair trade: long a healthcare-capex beneficiary with clearer pricing power, short Arjo as a relative-margin-lagging installer/manufacturer; hold 3-6 months and fade any rally driven by one-off order wins.
• Buy medium-dated call spreads on Arjo into any pre-strategy pullback if implied volatility stays compressed; the risk/reward improves if the market is not pricing a tangible 2H26 restructuring or simplification announcement.
• For event-driven investors, wait for the 2H26 strategy update before taking a directional long: upside case is a 10-15% rerating if execution priorities are concrete; downside is a flat stock if the update lacks measurable margin or capital-allocation commitments.